<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2605210755
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lamzede
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VELMANASE ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4666
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CHIESI FARMACEUTICIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CHIESI FARMACEUTICIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CHIESI FARMACEUTICIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AB15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lamzede contains the active substance velmanase alfa which belongs to a group of medicines known as enzyme replacement therapies. It is used to treat patients with mild to moderate alpha-mannosidosis disease. It is given for the treatment of non-neurological symptoms of the disease.</p><p>&nbsp;</p><p>Alpha-mannosidosis disease is a rare genetic disorder caused by a lack of an enzyme named</p><p>alpha-mannosidase, which is needed to break down certain sugar compounds (called &lsquo;mannose-rich oligosaccharides&rsquo;) in the body. When this enzyme is missing or does not work properly, these sugar compounds build up inside cells and cause the signs and symptoms of the disease. The typical manifestations of the disease include distinctive facial features, mental retardation, difficulty in controlling movements, difficulties in hearing and speaking, frequent infections, skeletal problems, muscle pain and weakness.</p><p>&nbsp;</p><p>Velmanase alfa is designed to replace the missing enzyme in patients with alpha-mannosidosis disease. This may improve the symptoms of the disease</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Lamzede must not be used:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to velmanase alfa or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before Lamzede is used.</p><p>If you are treated with Lamzede, you may experience a side effect during or immediately following the drip (infusion) used to give the medicine (see section 4). This is known as an <strong>infusion-related reaction </strong>and can sometimes be severe.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion-related reactions include dizziness, headache, nausea, low blood pressure, tiredness and fever. If you experience an infusion-related reaction, <strong>you must tell your doctor immediately</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an infusion-related reaction you may be given additional medicines to treat or help prevent future reactions. These medicines may include medicines used to treat allergies (antihistamines), medicines used to treat fever (antipyretics) and medicines to control inflammation (corticosteroids).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the infusion-related reaction is severe, your doctor will stop the infusion immediately and start giving you appropriate medical treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the infusion-related reactions are severe and/or there is a loss of effect from this medicine, your doctor will perform a blood test to check for antibodies that might affect the outcome of your treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most of the time you can still be given Lamzede even if you experience an infusion-related reaction.</p><p>&nbsp;</p><p><strong>Other medicines and Lamzede</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before this medicine is used.</p><p>&nbsp;</p><p>Lamzede should be used during pregnancy only when medically necessary. It is not known whether velmanase alfa passes into breast milk. Lamzede can be used during breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Lamzede has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Lamzede contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is only to be used under the supervision of a doctor experienced in the treatment of alpha-mannosidosis or other similar diseases and should only be given by a healthcare professional.</p><p>&nbsp;</p><p><strong>Dosage</strong></p><p>The recommended dose of Lamzede is 1 mg/kg of body weight given once every week.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Lamzede may be given to children and adolescents at the same dose and frequency as in adults. There is no experience with patients younger than 6 years of age.</p><p>&nbsp;</p><p><strong>Administration</strong></p><p>Lamzede is supplied in a vial as a powder for infusion which will be made up with water for injections before being given.</p><p>Once it has been made up, the medicine will be given by infusion pump (drip) into a vein over a period of at least 50 minutes under your doctor&rsquo;s supervision.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects occur during the infusion or shortly after (&ldquo;infusion-related reaction&rdquo;, see section 2 Warnings and precautions).</p><p>&nbsp;</p><p>While under treatment with Lamzede, you may experience some of the following reactions:</p><p>&nbsp;</p><p><strong><u>Serious side effects</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>side effects (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness (fainting, which may be preceded by feeling dizzy, lightheaded or confused)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute renal insufficiency (kidney problems which can be recognised from fluid retention, swelling in legs, ankles or feet, drowsiness, shortness of breath or fatigue)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity and serious allergic reaction (symptoms including localised or diffuse skin itching, dizziness, difficulty breathing, chest pain, gastrointestinal symptoms such as nausea, vomiting, diarrhea or intestinal pain, swelling of the throat, face, lips or tongue)</p><p>&nbsp;</p><p>If you experience any side effect like these, please tell your doctor immediately. <u>Other side effects</u></p><p><strong>Very common </strong>side effects (may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever/increased body temperature</p><p>&nbsp;</p><p><strong>Common </strong>side effects (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low heart beat (bradycardia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychotic behaviour (mental illness with hallucinations, difficulty in thinking clearly and understanding reality, anxiety), initial difficulty in sleeping</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confused state, fainting, tremor, dizziness, headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intestinal (abdominal) pain, irritation of the stomach caused by digestive acids (reflux gastritis), nausea, vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the site the infusion is given, chills, feeling hot, malaise, tiredness (fatigue)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes (urticaria), increased sweating (hyperhidrosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nosebleed</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain, back pain, joint stiffness, muscle pain, pain in extremity (hands, feet)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye irritation, eyelid swelling (eyelid oedema), eye redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased appetite</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><u>Please report adverse drug events to:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><p>The National Pharmacovigilance Centre (NPC): Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>SFDA Call Center:19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>https://ade.sfda.gov.sa</u></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and the carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store and transport refrigerated (2&deg;C - 8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>After reconstitution, the medicine should be used immediately. If not used immediately, the reconstituted solution may be stored up to 24 hours at 2&deg;C to 8&deg;C.</p><p>This medicine must not be used if the reconstituted solution contains <strong>opaque particles or is discoloured</strong>.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is velmanase alfa.</p><p>One vial contains 10 mg of velmanase alfa.</p><p>After reconstitution, one mL of the solution contains 2 mg of velmanase alfa (10 mg / 5 mL).</p><p>&nbsp;</p><p>The other ingredients are: disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, mannitol and glycine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lamzede is a white to off-white powder for solution for infusion, supplied in a glass vial. Each carton contains 1, 5 or 10 vials.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Chiesi Farmaceutici S.p.A. Via Palermo 26/A</p><p>43122 Parma Italy</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Patheon Italia S.p.A.</p><p>2&deg; Trav. SX Via Morolense, 5,</p><p>03013 Ferentino FR Italy</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Final Batch Releaser </strong></p><p>Chiesi Farmaceutici S.p.A. Via San Leonardo, 96 43122 Parma</p><p>Italy</p><p>&nbsp;</p><p>For more information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Biologix, FzCo, Dubai Free Zone,</p><p>Road WB 21, warehouse C17 PO Box 54405 Al Tawwar Building , United Arab Emirates.Tel: (971) 4 299 7171.Email: Pharmacovigilance@blgx.net</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي لامزيد على المادة الفعالة فلماناس ألفا، وهو ينتمي إلى فئة الأدوية التي تسمى علاجات استبدال الإنزيم. ويُستخدم لعلاج المرضى المصابين بمرض ألفا-مانوسيدوسيس الخفيف إلى المتوسط. ويُعطى الدواء لعلاج الأعراض غير العصبية للمرض.</p><p dir="RTL">مرض ألفا-مانوسيدوسيس هو اضطراب جيني نادر يحدث نتيجة لنقص إنزيم يطلق عليه اسم ألفا-مانوسيداز، وهو ضروري لتكسير مركبات محددة في السكر (تسمى &quot;السكريات قليلة التعدد الغنية بالمانوز&quot;) في الجسم. وفي حالة غياب هذا الإنزيم أو عدم أدائه لوظيفته بشكل صحيح، تتراكم هذه المركبات السكرية داخل الخلايا وتسبب ظهور علامات المرض وأعراضه. والمظاهر المعتادة للإصابة بالمرض تتضمن بعض السمات المميزة في الوجه، والتخلف العقلي، وصعوبة في التحكم في الحركات، وصعوبة في السمع والكلام، والتهابات متكررة، ومشكلات في الهيكل العظمي، وألمًا في العضلات، والضعف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن فلماناس ألفا مصمم لتعويض الإنزيم المفقود لدى المرضى المصابين بمرض ألفا-مانوسيدوسيس، وهو ما قد يحسِّن أعراض هذا المرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام لامزيد:</strong></p><p dir="RTL">- &nbsp;&nbsp;إذا كنت تعاني من الحساسية من فلماناس ألفا أو من أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك قبل تناول لامزيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال تم علاجك باستخدام لامزيد، فقد تشعر بعارض جانبي أثناء أو مباشرةً بعد &nbsp;الحقن (الغرس) المستخدم لإعطاء الدواء (انظر القسم 4). ويُعرف هذا برد الفعل المرتبط بالحقن ويمكن أن يكون حادًّا في بعض الأوقات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتتضمن ردود الفعل المرتبطة بالحقن الدوخة، الصداع، الغثيان، انخفاض أو ارتفاع ضغط الدم، الإعياء، الحمى. وإذا شعرت برد فعل مرتبط بالحقن، يجب إعلام طبيبك على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من رد فعل مرتبط بالحقن، فقد يتم إعطاؤك مزيدًا من الأدوية لعلاج رد الفعل أو المساعدة في الوقاية منه في المستقبل. وقد تتضمن هذه العقاقير الأدوية المستخدمة لعلاج أنواع الحساسية (مضادات الهيستامين)، والأدوية المستخدمة لعلاج الحمى (خافضات الحرارة)، وأدوية علاج الالتهابات (الستيرويدات القشرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان رد الفعل المرتبط بالحقن حادًّا، فسيوقف طبيبك الحقن على الفور وسيبدأ في إعطائك علاجًا طبيًّا ملائمًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان رد الفعل المرتبط بالحقن حادًّا أو في حالة عدم إحداث هذا الدواء تأثيرًا، فسيجري طبيبك اختبارًا للدم للتحقق من وجود الأجسام المضادة التي قد تؤثر في نتيجة العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن الاستمرار في تناول لامزيد في معظم الحالات، حتى في حالة حدوث رد فعل مرتبط بالحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ولامزيد</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">في حالة الحمل أو الرضاعة الطبيعية أو توقع حدوث حمل أو التخطيط لذلك، قومي باستشارة طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجب استخدام لامزيد أثناء الحمل، إلا في حالة الضرورة الطبية. ومن غير المعروف ما إذا كان فلماناس ألفا يتسرب في حليب الثدي. ويمكن استخدام لامزيد أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلآت</strong></p><p dir="RTL">لامزيد ليس له أي تأثير يُذكر على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لامزيد يحتوي على الصوديوم</strong></p><p>هذا الدواء يحتوي على أقل من 1 مليمول صوديوم (23 ملغ) لكل وحدة جرعة، وهذا يعني أن &quot;الدواء خالٍ من الصوديوم&quot; بدرجة كبيرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا يُستخدم هذا الدواء إلا تحت إشراف طبيب خبير في علاج ألفا-مانوسيدوسيس أو أمراض أخرى مشابهة، ولا يُقدم إلا من جانب مختص في الرعاية الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الجرعة</strong></p><p dir="RTL">الجرعة الموصى بها من لامزيد هي 1 ملغ/كلغ من وزن الجسم مرة واحدة أسبوعيًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في حالة الأطفال والمراهقبن</strong></p><p dir="RTL">يمكن إعطاء لامزيد للأطفال والمراهقين بالجرعة نفسها وعدد المرات تمامًا مثل البالغين. ولم يُختبر الدواء على المرضى دون 6 سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة إعطاء الدواء</strong></p><p dir="RTL">يتوفر الدواء في قارورة في شكل مسحوق للحقن ويُحل بماء الحقن قبل إعطائه.</p><p dir="RTL">بمجرد حله، يُعطى الدواء عن طريق مضخة الحقن في الوريد في مدة زمنية لا تقل عن 50 دقيقة تحت إشراف الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إذا كانت لديك أي أسئلة أخرى عن استخدام هذا الدواء، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، قد يسبب هذا الدواء أعراضًا جانبية على الرغم من عدم حدوثها لكل الأشخاص. وتحدث معظم الأعراض الجانبية خلال الحقن أو بعد فترة وجيزة منه (&quot;رد الفعل المرتبط بالحقن&quot;، انظر القسم 2 التحذيرات والاحتياطات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في أثناء العلاج بلامزيد، قد تشعر ببعض ردات الفعل التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>أعراض جانبية خطيرة</u></strong></p><p dir="RTL">الأعراض الجانبية <strong>الشائعة</strong> (قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي (الإغماء الذي قد يسبقه الشعور بالدوار أو خفة الرأس أو ارتباك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القصور الكلوي الحاد (مشكلات الكلى التي يمكن التعرف عليها من خلال احتباس السوائل وورم الساقين أو الكاحلين أو القدمين أو النعاس أو ضيق التنفس أو التعب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية ورد الفعل التحسسي الخطير (تتضمن الأعراض حكة الجلد الموضعي أو المنتشر، الدوار، صعوبة التنفس، ألم الصدر، أعراض الجهاز الهضمي مثل الغثيان أو القيء أو الإسهال أو ألم معوي أو ورم الحلق أو الوجه أو الشفتين أو اللسان)</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>إذا شعرت بأي أعراض جانبية مشابهة، يرجى إخبار الطبيب على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>أعراض جانبية أخرى</u></strong></p><p dir="RTL">أعراض جانبية <strong>شائعة جدًّا</strong> (قد يؤثر على أكثر من 1 في 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى/ارتفاع درجة حرارة الجسم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;أعراض جانبية <strong>شائعة</strong> (قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف نبضات القلب (بطء القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلوك الذهاني (مرض عقلي مع هلوسة وصعوبة التفكير بوضوح وإدراك الواقع، القلق)، وصعوبة أولية في النوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة ارتباك، إغماء، رعشة، دوخة، صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم معوي (في البطن)، تهيج في المعدة نتيجة لأحماض الهضم (التهاب معدي ارتجاعي)، غثيان، قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع إدخال الحقن، قشعريرة، الشعور بالحر، توعك، إعياء (تعب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (شرى)، زيادة التعرق (فرط التعرق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل، ألم الظهر، تيبس المفاصل، ألم العضلات، ألم في الأطراف (اليدين، القدمين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العين، تورم جفن العين (وذمة جفن العين)، احمرار العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا تفاقمت حدة أي من الأعراض الجانبية، يرجى إعلام طبيبك. ويشمل هذا أي أعراض جانبية غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في تقديم مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">للإبلاغ عن أي عرض جانبي(أعراض جانبية):</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المركز&nbsp;<em>الوطني</em>&nbsp;للتيقظ والسلامة الدوائية &nbsp;(NPC)</p><p dir="RTL">فاكس: 7662-205-11-966+</p><p dir="RTL">اتصل&nbsp;بالمركز&nbsp;<em>الوطني</em>&nbsp;للتيقظ والسلامة الدوائية &nbsp;(NPC) على 2038222-11-966+, داخلى: 2317-2356-2340</p><p dir="RTL">الخط الساخن: ١٩٩٩٩</p><p dir="RTL">البريد الإليكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: :&nbsp; https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق والعبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن ويُنقل في حالة تبريد (2 درجة مئوية - 8 درجات مئوية).</p><p dir="RTL">يُخزن في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">بعد تركيب الدواء، يجب أن يتم استخدامه في الحال. وفي حالة عدم استخدامه فورًا، يمكن الاحتفاظ بالمحلول المجهز حتى 24 ساعة في درجة حرارة تتراوح بين 2 درجة مئوية و8 درجة مئوية.</p><p dir="RTL">يجب عدم استخدام هذا الدواء إذا كان المحلول المجهز <strong>محتويًا على جزيئات غير شفافة أو قد تغير لونه.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي دواء عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة لاستخدامها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوي لامزيد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المادة الفعالة هي فلماناس ألفا.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي القارورة الواحدة على 10 ملغ من فلماناس ألفا.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد تركيب الدواء، يحتوي كل ملل من المحلول على 2 ملغ من فلماناس ألفا (10 ملغ / 5 ملل).</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المكونات الأخرى هي: ثنائي هيدرات فوسفات ثنائي الصوديوم، وثنائي هيدرات فوسفات ثنائي هيدروجين الصوديوم، مانيتول، وجلايسين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما </strong>&nbsp;<strong>هو ال</strong><strong>شكل الصيدلاني للامزيد وصفه وما محتوى عبوته</strong></p><p dir="RTL">&nbsp;لامزيد عبارة عن مسحوق لمحلول الحقن باللون أبيض إلى الأبيض الفاتح، متوفر في قارورة زجاجية.</p><p dir="RTL">&nbsp;تحتوي كل علبة على 1 أو 5 أو 10 قارورات.</p><p dir="RTL">&nbsp;قد لا تكون جميع الأحجام متوفرة في السوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة تسويق</strong></p><p>&nbsp;Chiesi Farmaceutici S.p.A.</p><p>Via Palermo 26/A</p><p>43122 Parma</p><p dir="RTL">Italy</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مصنع الشكل الصيدلاني</strong></p><p>Patheon Italia S.p.A.</p><p>2&deg; Trav. SX Via Morolense, 5, 03013</p><p>Ferentino FR,</p><p dir="RTL">Italy</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع المسؤول عن تحرير الصنف</strong></p><p>Chiesi Farmaceutici S.p.A.</p><p>Via San Leonardo, 96</p><p>43122 Parma</p><p>Italy</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أية معلومات عن هذا الدواء، يرجى الاتصال بالممثل المحلي للشركة المالكة رخصة تسويق:</p><p>Biologix, FzCo, Dubai Free Zone,</p><p>Road WB 21, warehouse C17 PO Box 54405 Al Tawwar Building , United Arab Emirates.Tel: (971) 4 299 7171.Email: Pharmacovigilance@blgx.net</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة بتاريخ 11/2018.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lamzede 10 mg powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 10 mg of velmanase alfa*.
After reconstitution, one mL of the solution contains 2 mg of velmanase alfa (10 mg / 5 mL). For the full list of excipients, see section 6.1.
*Velmanase alfa is produced in mammalian Chinese Hamster Ovary (CHO) cells using recombinant DNA technology.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion. White to off-white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis. See sections 4.4 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment should be supervised by a physician experienced in the management of patients with alpha-mannosidosis or in the administration of other enzyme replacement therapies (ERT) for lysosomal storage disorder. Administration of Lamzede should be carried out by a healthcare professional with the ability to manage ERT and medical emergencies.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose regimen is 1 mg/kg of body weight administered once every week by intravenous infusion at a controlled speed. For infusion rate see section &ldquo;Method of administration&rdquo;.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Renal or hepatic impairment</em></p><p>No dose adjustment is necessary for patients with renal or hepatic impairment.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No data are available and no relevant use in elderly patients is described.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>No dose adjustment is necessary for the paediatric population. <u>Method of administration</u></p><p>For intravenous infusion use only.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p><p>The reconstituted solution of Lamzede should be administered using an infusion set equipped with a pump and an in-line low protein-binding 0.22 &micro;m filter. The infusion duration should be calculated individually considering a maximum infusion rate of 25 mL/hour to control the protein load. The infusion duration should be a minimum of 50 minutes. A slower infusion rate may be prescribed when clinically appropriate according to the physician&rsquo;s judgment, for example at the beginning of the treatment or in case of previous infusion-related reactions (IRRs).</p><p>For the calculation of the infusion rate and the infusion time based on body weight see the table in section 6.6.</p><p>&nbsp;</p><p>The patient should be observed for IRRs for at least one hour after the infusion according to clinical conditions and the physician&rsquo;s judgment. For further instructions, see section 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Severe allergic reaction to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of treatment with velmanase alfa should be periodically evaluated and discontinuation of treatment considered in cases where no clear benefits could be observed.</p><p>&nbsp;</p><p>As the accumulation of end organ damage progresses over time, it is more difficult for the treatment to reverse the damage or to show improvements. As with other enzyme replacement therapies, velmanase alfa does not cross the blood-brain-barrier. It should be considered by the treating physician that the administration of velmanase alfa does not affect the irreversible complications (i.e. skeletal deformities, disostosis multiplex, neurological manifestations and impaired cognitive function).</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>Hypersensitivity reactions have been reported in patients in clinical studies. Appropriate medical support should be readily available when velmanase alfa is administered. If severe allergic or anaphylactic-type reactions occur, immediate discontinuation of velmanase alfa is recommended and current medical standards for emergency treatment are to be followed.</p><p>&nbsp;</p><p><u>Infusion-related reaction</u></p><p>&nbsp;</p><p>Administration of velmanase alfa may result in an IRR, including anaphylactoid reaction (see</p><p>section 4.8). The IRRs observed in clinical studies of velmanase alfa were characterised by a rapid onset of symptoms and were of mild to moderate severity.</p><p>&nbsp;</p><p>The management of IRRs should be based on the severity of the reaction and includes slowing the infusion rate, treatment with medicinal products such as antihistamines, antipyretics and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. Pre-treatment with antihistamines and/or corticosteroids may prevent subsequent reactions in those cases where symptomatic treatment was required. Patients were not routinely pre-medicated prior to infusion of velmanase alfa during clinical studies.</p><p>&nbsp;</p><p>In case symptoms such as angioedema (tongue or throat swelling), upper airway obstruction or hypotension occur during or immediately after infusion, anaphylaxis or an anaphylactoid reaction should be suspected. In such a case, treatment with an antihistamine and corticosteroids should be considered as being appropriate. In the most severe cases, the current medical standards for emergency treatment are to be observed.</p><p>&nbsp;</p><p>The patient should be kept under observation for IRRs for one hour or longer after the infusion, according to the treating physician&rsquo;s judgement.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>Antibodies may play a role in treatment-related reactions observed with the use of velmanase alfa. To further evaluate the relationship, in instances of development of severe IRRs or lack or loss of treatment effect, patients should be tested for the presence of anti-velmanase alfa antibodies. In case the patient&rsquo;s condition deteriorates during ERT, cessation of treatment should be considered.</p><p>&nbsp;</p><p>There is a potential for immunogenicity. In the clinical studies at any time under treatment, 8 patients out of 33 (24%) developed IgG-class antibodies to velmanase alfa. No clear correlation was found between antibody titres (velmanase alfa IgG antibody level) and reduction in efficacy or occurrence of anaphylaxis or other hypersensitivity reactions.</p><p>The development of antibodies has not been shown to affect clinical efficacy or safety. <u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of velmanase alfa in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). As velmanase alfa aims at normalizing alpha-mannosidase in alpha-mannosidosis patients, Lamzede should be used during pregnancy only when strictly needed.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether velmanase alfa or its metabolites are excreted in human milk. Nevertheless, the absorption of any ingested milk-containing velmanase alfa in the breastfed child is considered to be minimal and no untoward effects are therefore anticipated. Lamzede can be used during breastfeeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no clinical data on the effects of velmanase alfa on fertility. Animal studies do not show evidence of impaired fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lamzede has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most common adverse reactions observed were weight increase (18%), IRRs (9%), diarrhoea (12%), headache (9%), arthralgia (9%), increased appetite (6%) and pain in extremity (6%).</p><p>All of these adverse reactions were non-serious. IRRs include hypersensitivity in 3 patients and anaphylactoid reaction in 1 patient. These reactions were non-serious and mild to moderate in intensity. A total of 2 serious adverse reactions (loss of consciousness in 1 patient and acute renal failure in</p><p>1 patient) were observed. In both cases the patients recovered without sequelae. <u>Tabulated list of adverse reactions</u></p><p>The adverse reactions reflecting exposure of 33 patients treated with velmanase alfa in clinical studies are listed in the table 1 below. Adverse reactions are classified by system organ class and preferred term according to the MedDRA frequency convention. Frequency is defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) or not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 1: Adverse reactions reported in clinical studies in patients with alpha-mannosidosis treated with velmanase alfa</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactoid reaction<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>Increased appetite</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>Psychotic behaviour</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Initial insomnia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Loss of consciousness<sup>(2<strong>)</strong></sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:66.4pt;margin-top:-395pt;width:479.6pt;
 height:394.05pt;z-index:251654144;mso-position-horizontal-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>Eye irritation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Eyelid oedema</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Ocular hyperaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders</em></p></td><td style="vertical-align:top"><p>Bradycardia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain upper</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea<sup>(1<strong>)</strong></sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Reflux gastritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>Urticaria<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Joint stiffness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>Renal failure acute<sup>(2)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><em>General disorder and administration site conditions</em></p></td><td style="vertical-align:top"><p>Pyrexia<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Catheter site pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Chills<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Feeling hot<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Malaise<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Investigations</em></p></td><td style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p><em>Injury, poisoning and procedural complications</em></p></td><td style="vertical-align:top"><p>Procedural headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><p><sup>(1)</sup> Preferred terms considered as IRR as described in the section below</p><p><sup>(2)</sup> Selected adverse reaction as described in the section below <u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Infusion-related reaction</em></p><p>IRRs (including hypersensitivity, nausea, vomiting, pyrexia, chills, feeling hot, malaise, urticaria, anaphylactoid reaction and hyperhidrosis) were reported in 9% of the patients (3 out of 33 patients) in clinical studies. All were mild or moderate in severity and none were reported as a serious adverse event. All patients who experienced IRRs recovered.</p><p>&nbsp;</p><p><em>Acute renal failure</em></p><p>In the clinical studies, one patient experienced acute renal failure considered possibly related to the study treatment. Acute renal failure was of moderate severity leading to temporary discontinuation of the study treatment and fully resolved within 3 months. Concomitant long-term treatment with high doses of ibuprofen was noted as a potentially causative contributor to the occurrence of the event.</p><p>&nbsp;</p><p><em>Loss of consciousness</em></p><p>In one patient, loss of consciousness considered related to the study treatment with recovery after a few seconds was reported. The patient received saline infusion in a hospital setting and was then discharged after 6-hour observation.</p><p>The patient later experienced epileptic seizures that were considered not related.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety profile of velmanase alfa in clinical studies involving children and adolescents was similar to that observed in adult patients. Overall, 58% of patients (19 out of 33) with alpha-mannosidosis receiving velmanase alfa in clinical studies were aged 6 to 17 years at the start of the study.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To reports any side effect(s):</p><p>&middot;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><p>-&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC) o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o&nbsp; SFDA Call Center: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: https://ade.sfda.gov.sa/</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:79.1pt;
  margin-top:13.4pt;width:466.4pt;height:77.9pt;z-index:-251658240;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".16936mm">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.15pt;margin-right:226.1pt;
     margin-bottom:0in;margin-left:33.45pt;margin-bottom:.0001pt;text-indent:
     -14.2pt;line-height:97%;mso-list:l0 level1 lfo1;tab-stops:31.45pt'><![if !supportLists]><span
     style='font-size:11.5pt;line-height:97%;font-family:Symbol;mso-fareast-font-family:
     Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>The<span style='letter-spacing:-.2pt'> </span>National<span
     style='letter-spacing:-.1pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.2pt'> </span>Centre<span style='letter-spacing:
     -.15pt'> </span>(NPC)<span style='letter-spacing:-2.6pt'> </span>o Fax:<span
     style='letter-spacing:-.1pt'> </span>+966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:33.45pt;margin-bottom:.0001pt'>o Call<span
     style='letter-spacing:-.1pt'> </span>NPC<span style='letter-spacing:-.1pt'>
     </span>at<span style='letter-spacing:-.1pt'> </span>+966-11-2038222, Exts:<span
     style='letter-spacing:-.05pt'> </span>2317-2356-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:41.75pt;margin-bottom:.0001pt;text-indent:-8.35pt;
     line-height:12.6pt;mso-line-height-rule:exactly;mso-list:l0 level2 lfo1;
     tab-stops:41.8pt'><![if !supportLists]><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=LTR></span>SFDA<span style='letter-spacing:-.1pt'> </span>Call Center:<span
     style='letter-spacing:-.15pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:41.75pt;text-indent:-8.35pt;
     line-height:12.6pt;mso-line-height-rule:exactly;mso-list:l0 level2 lfo1;
     tab-stops:41.8pt'><![if !supportLists]><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=LTR></span>E-mail:<span style='letter-spacing:-.15pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:41.75pt;margin-bottom:.0001pt;text-indent:-8.35pt;
     mso-list:l0 level2 lfo1;tab-stops:41.8pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.35pt'> </span>https://ade.sfda.gov.sa/<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&middot;&nbsp; <strong><em>Other GCC states:</em></strong></p><p>- Please contact the relevant competent Authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdose of velmanase alfa. The maximum dose of velmanase alfa in clinical studies was a single administration of 100 units/kg (approximately corresponding to 3.2 mg/kg). During the infusion with this higher dose, fever of mild intensity and short duration (5 hours) was observed in one patient. No treatment was administered.</p><p>&nbsp;</p><p>For the management of adverse reactions, see sections 4.4 and 4.8.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other alimentary tract and metabolism products, enzymes. ATC code: A16AB15.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Velmanase alfa, the active substance of Lamzede, is a recombinant form of human alpha-mannosidase. The amino acid sequence of the monomeric protein is identical to the naturally occurring human enzyme, alpha-mannosidase.</p><p>Velmanase alfa is intended to supplement or replace natural alpha-mannosidase, an enzyme that catalyses the sequential degradation of hybrid and complex high-mannose oligosaccharides in the lysosome, reducing the amount of accumulated mannose-rich oligosaccharides.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>A total of 33 patients (20 males and 13 females, ranging in age from 6 to 35 years) were exposed to velmanase alfa in five clinical studies. Patients were diagnosed based on alpha-mannosidase activity</p><p>&lt;10% of normal activity in blood leukocytes. Patients with the most severe rapidly progressing phenotype (with a deterioration within one year and central nervous system involvement) were excluded. Based on this criteria mild to moderate patients, presenting heterogeneous severity with ability to perform endurance tests, large variability of clinical manifestations and age of onset were enrolled.</p><p>&nbsp;</p><p>Overall effects of treatment were evaluated in the domains of pharmacodynamics (reduction of serum oligosaccharides), functional (three-minute stair climbing test (3MSCT), six-minute walking test (6MWT), and forced vital capacity (FVC) % predicted) and quality of life (childhood health assessment questionnaire (CHAQ) disability index (DI) and CHAQ VAS pain (visual analogue scale)).</p><p>&nbsp;</p><p>In the phase 3 pivotal multi-centre, double-blind, randomised, placebo-controlled, parallel group study rhLAMAN-05, the efficacy and safety of repeated administrations of velmanase alfa over 52 weeks at a dose of 1 mg/kg given weekly as intravenous infusion were investigated. A total of 25 patients were enrolled, including 12 paediatric subjects (age range: 6 to 17 years; mean: 10.9 years) and 13 adult subjects (age range: 18 to 35 years; mean: 24.6). All but one patient were na&iuml;ve to the treatment with velmanase alfa. In total 15 patients (7 paediatrics and 8 adults) received active treatment and 10 patients received placebo (5 paediatrics and 5 adults). The results (serum oligosaccharide concentration, 3MSCT, 6MWT and FVC%) are presented in table 2. A pharmacodynamic effect with statistically significant decrease of serum oligosaccharides in comparison to placebo was demonstrated. The results observed in patients below 18 years of age showed an improvement. In patients over 18 years old a stabilisation has been demonstrated. The numerical improvement of most clinical endpoints over placebo (2 to 8 %) observed in the year of observation could be suggestive of the ability of velmanase alfa to slow down the existing disease progression.</p><p>&nbsp;</p><p><strong>Table 2: Results from placebo-controlled clinical study rhLAMAN-05 (source data: rhLAMAN-05)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment with velmanase alfa for 12 months</strong></p><p><strong>(n=15)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment with placebo for 12 months (n=10)</strong></p></td><td style="vertical-align:top"><p><strong>Velmanase alfa vs. placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients</strong></p></td><td style="vertical-align:top"><p><strong>Baseline actual value Mean (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Absolute change from baseline Mean</strong></p></td><td style="vertical-align:top"><p><strong>Baseline actual value Mean (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Absolute change from baseline Mean</strong></p></td><td style="vertical-align:top"><p><strong>Adjusted mean difference</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Serum oligosaccharide concentration (&mu;mol/l)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall<sup>(1)</sup></strong></p></td><td style="vertical-align:top"><p>6.8 (1.2)</p></td><td style="vertical-align:top"><p>-5.11</p></td><td style="vertical-align:top"><p>6.6 (1.9)</p></td><td style="vertical-align:top"><p>-1.61</p></td><td style="vertical-align:top"><p>-3.50</p></td></tr><tr><td style="vertical-align:top"><p>[95% CI]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[-5.66; -4.56]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[-2.28; -0.94]</p></td><td style="vertical-align:top"><p>[-4.37; -2.62]</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>p&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>7.3 (1.1)</p></td><td style="vertical-align:top"><p>-5.2 (1.5)</p></td><td style="vertical-align:top"><p>6.0 (2.4)</p></td><td style="vertical-align:top"><p>-0.8 (1.7)</p></td><td rowspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>6.3 (1.1)</p></td><td style="vertical-align:top"><p>-5.1 (1.0)</p></td><td style="vertical-align:top"><p>7.2 (1.0)</p></td><td style="vertical-align:top"><p>-2.4 (1.4)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>3MSCT (steps/min)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall<sup>(1)</sup></strong></p></td><td style="vertical-align:top"><p>52.9 (11.2)</p></td><td style="vertical-align:top"><p>0.46</p></td><td style="vertical-align:top"><p>55.5 (16.0)</p></td><td style="vertical-align:top"><p>-2.16</p></td><td style="vertical-align:top"><p>2.62</p></td></tr><tr><td style="vertical-align:top"><p>[95% CI]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[-3.58; 4.50]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[-7.12; 2.80]</p></td><td style="vertical-align:top"><p>[-3.81; 9.05]</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>p=0.406</p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>56.2 (12.5)</p></td><td style="vertical-align:top"><p>3.5 (10.0)</p></td><td style="vertical-align:top"><p>57.8 (12.6)</p></td><td style="vertical-align:top"><p>-2.3 (5.4)</p></td><td rowspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>50.0 (9.8)</p></td><td style="vertical-align:top"><p>-1.9 (6.7)</p></td><td style="vertical-align:top"><p>53.2 (20.1)</p></td><td style="vertical-align:top"><p>-2.5 (6.2)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>6MWT (metres)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall<sup>(1)</sup></strong></p></td><td style="vertical-align:top"><p>459.6 (72.26)</p></td><td style="vertical-align:top"><p>3.74</p></td><td style="vertical-align:top"><p>465.7 (140.5)</p></td><td style="vertical-align:top"><p>-3.61</p></td><td style="vertical-align:top"><p>7.35</p></td></tr><tr><td style="vertical-align:top"><p>[95% CI]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[-20.32; 27.80]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[-33.10; 25.87]</p></td><td style="vertical-align:top"><p>[-30.76; 45.46]</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>p=0.692</p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>452.4 (63.9)</p></td><td style="vertical-align:top"><p>12.3 (43.2)</p></td><td style="vertical-align:top"><p>468.8 (79.5)</p></td><td style="vertical-align:top"><p>3.6 (43.0)</p></td><td rowspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>465.9 (82.7)</p></td><td style="vertical-align:top"><p>-2.5 (50.4)</p></td><td style="vertical-align:top"><p>462.6 (195.1)</p></td><td style="vertical-align:top"><p>-12.8 (41.6)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>FVC (% of predicted)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall<sup>(1)</sup></strong></p></td><td style="vertical-align:top"><p>81.67 (20.66)</p></td><td style="vertical-align:top"><p>8.20</p></td><td style="vertical-align:top"><p>90.44 (10.39)</p></td><td style="vertical-align:top"><p>2.30</p></td><td style="vertical-align:top"><p>5.91</p></td></tr><tr><td style="vertical-align:top"><p>[95% CI]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[1.79; 14.63]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[-6.19; 10.79]</p></td><td style="vertical-align:top"><p>[-4.78; 16.60]</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>p=0.278</p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>69.7 (16.8)</p></td><td style="vertical-align:top"><p>14.2 (8.7)</p></td><td style="vertical-align:top"><p>88.0 (10.9)</p></td><td style="vertical-align:top"><p>8.0 (4.2)</p></td><td rowspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;18 years<sup>(2)</sup></strong></p></td><td style="vertical-align:top"><p>93.7 (17.7)</p></td><td style="vertical-align:top"><p>2.2 (7.2)</p></td><td style="vertical-align:top"><p>92.4 (10.8)</p></td><td style="vertical-align:top"><p>-2.8 (15.5)</p></td></tr></tbody></table><p><strong><sup>(1)</sup> </strong>For overall: adjusted mean change and adjusted mean difference estimated by ANCOVA model are presented</p><p><strong><sup>(2)</sup> </strong>By age: unadjusted mean and SD are presented.</p><p>The long-term efficacy and safety of velmanase alfa was investigated in the uncontrolled, open label, phase 3 clinical study rhLAMAN-10 in 33 subjects (19 paediatrics and 14 adults, from 6 to 35 years at treatment initiation) who previously participated in velmanase alfa studies. An integrated database was created by pooling cumulative databases from all studies with velmanase alfa. Statistically significant improvements were detected in serum oligosaccharide levels, 3MSCT, pulmonary function, serum IgG and EQ-5D-5L (euro quality of life-5 dimensions) over time, up to the last observation (table 3). The effects of velmanase alfa were more evident in patients younger than 18 years.</p><p>&nbsp;</p><p><strong>Table 3: Change of clinical endpoints from baseline to the last observation in rhLAMAN-10 study (source data: rhLAMAN-10)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Patients n=33</strong></p></td><td style="vertical-align:top"><p><strong>Baseline actual value Mean</strong></p><p><strong>(SD)</strong></p></td><td style="vertical-align:top"><p><strong>Last observation</strong></p><p><strong>% change from baseline</strong></p><p><strong>(SD)</strong></p></td><td style="vertical-align:top"><p><strong>p-value [95% CI]</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Serum oligosaccharide</strong></p></td><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>6.90</p></td><td style="vertical-align:top"><p>-62.8</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>concentration (&micro;mol/L)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(2.30)</p></td><td style="vertical-align:top"><p>(33.61)</p></td><td style="vertical-align:top"><p>[-74.7; -50.8]</p></td></tr><tr><td style="vertical-align:top"><p><strong>3MSCT (steps/min)</strong></p></td><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>53.60</p></td><td style="vertical-align:top"><p>13.77</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(12.53)</p></td><td style="vertical-align:top"><p>(25.83)</p></td><td style="vertical-align:top"><p>[4.609; 22.92]</p></td></tr><tr><td style="vertical-align:top"><p><strong>6MWT (metres)</strong></p></td><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>466.6</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>0.071</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(90.1)</p></td><td style="vertical-align:top"><p>(22.0)</p></td><td style="vertical-align:top"><p>[-0.7; 14.9]</p></td></tr><tr><td style="vertical-align:top"><p><strong>FVC (% of predicted)</strong></p></td><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>84.9</p></td><td style="vertical-align:top"><p>10.5</p></td><td style="vertical-align:top"><p>0.011</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(18.6)</p></td><td style="vertical-align:top"><p>(20.9)</p></td><td style="vertical-align:top"><p>[2.6; 18.5]</p></td></tr></tbody></table><p><strong>&nbsp;</strong>Data suggest that the beneficial effects of the treatment with velmanase alfa diminish with the increase of disease burden and disease-related respiratory infections.</p><p>A post-hoc multiparametric responders analysis supports the benefit of longer treatment with velmanase alfa in 87.9% of responders in at least 2 domains at last observation (table 4).</p><p>&nbsp;</p><p><strong>Table 4: Multiparametric responder analysis: MCID<sup>(1)</sup> Responders Rates by Endpoints and Domains (source data: rhLAMAN-05; rhLAMAN-10)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Domain</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Criterion</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Responders Rates</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>rhLAMAN-05 study n=25</strong></p></td><td style="vertical-align:top"><p><strong>rhLAMAN-10 study n=33</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Placebo 12 months</strong></p></td><td style="vertical-align:top"><p><strong>Lamzede 12 months</strong></p></td><td style="vertical-align:top"><p><strong>Lamzede Last Observation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pharmacodynamic</p></td><td style="vertical-align:top"><p>Oligosaccharides</p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>100%</p></td><td style="vertical-align:top"><p>91.0%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pharmacodynamic Domain Response</strong></p></td><td style="vertical-align:top"><p><strong>Oligosaccharides</strong></p></td><td style="vertical-align:top"><p><strong>20.0%</strong></p></td><td style="vertical-align:top"><p><strong>100%</strong></p></td><td style="vertical-align:top"><p><strong>91.0%</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Functional</p></td><td style="vertical-align:top"><p>3MSCT</p></td><td style="vertical-align:top"><p>10.0%</p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>48.5%</p></td></tr><tr><td style="vertical-align:top"><p>6MWT</p></td><td style="vertical-align:top"><p>10.0%</p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>48.5%</p></td></tr><tr><td style="vertical-align:top"><p>FVC (%)</p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>33.3%</p></td><td style="vertical-align:top"><p>39.4%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Functional Domain Response</strong></p></td><td style="vertical-align:top"><p><strong>Combined</strong></p></td><td style="vertical-align:top"><p><strong>30.0%</strong></p></td><td style="vertical-align:top"><p><strong>60.0%</strong></p></td><td style="vertical-align:top"><p><strong>72.7%</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Quality of Life</p></td><td style="vertical-align:top"><p>CHAQ-DI</p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>42.2%</p></td></tr><tr><td style="vertical-align:top"><p>CHAQ-VAS</p></td><td style="vertical-align:top"><p>33.3%</p></td><td style="vertical-align:top"><p>40.0%</p></td><td style="vertical-align:top"><p>45.5%</p></td></tr><tr><td style="vertical-align:top"><p><strong>QoL Domain</strong></p></td><td style="vertical-align:top"><p><strong>Combined</strong></p></td><td style="vertical-align:top"><p><strong>40.0%</strong></p></td><td style="vertical-align:top"><p><strong>40.0%</strong></p></td><td style="vertical-align:top"><p><strong>66.7%</strong></p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:71.3pt;margin-top:-118.7pt;width:470.5pt;
 height:123.75pt;z-index:251655168;mso-position-horizontal-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Domain</strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Criterion</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Responders Rates</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>rhLAMAN-05 study n=25</strong></p></td><td style="vertical-align:top"><p><strong>rhLAMAN-10 study n=33</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>12 months</strong></p></td><td style="vertical-align:top"><p><strong>Lamzede</strong></p><p><strong>12 months</strong></p></td><td style="vertical-align:top"><p><strong>Lamzede</strong></p><p><strong>Last Observation</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Overall response</strong></p></td><td style="vertical-align:top"><p><strong>Three domains</strong></p></td><td style="vertical-align:top"><p><strong>0</strong></p></td><td style="vertical-align:top"><p><strong>13.3%</strong></p></td><td style="vertical-align:top"><p><strong>45.5%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Two domains</strong></p></td><td style="vertical-align:top"><p><strong>30.0%</strong></p></td><td style="vertical-align:top"><p><strong>73.3%</strong></p></td><td style="vertical-align:top"><p><strong>42.4%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>One domain</strong></p></td><td style="vertical-align:top"><p><strong>30.0%</strong></p></td><td style="vertical-align:top"><p><strong>13.3%</strong></p></td><td style="vertical-align:top"><p><strong>9.1%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>No domains</strong></p></td><td style="vertical-align:top"><p><strong>40.0%</strong></p></td><td style="vertical-align:top"><p><strong>0</strong></p></td><td style="vertical-align:top"><p><strong>3.0%</strong></p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><p><sup>(1)</sup> MCID: minimal clinically important difference.</p><p>&nbsp;</p><p>&nbsp;<u>Paediatric population</u></p><p>Use of velmanase alfa in the age group 6 to 17 years is supported by evidence from clinical studies in paediatric (19 out of 33 patients) and adult patients. No clinical data are available in children below the age of 6 years.</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Lamzede in one or more subsets of the paediatric population in the treatment of alpha-mannosidosis disease (see section 4.2 for information on paediatric use).</p><p>This medicinal product has been authorised under &lsquo;exceptional circumstances&rsquo;. This means that due to the rarity of the disease, it has not been possible to obtain complete information on this medicinal product.</p><p>The European Medicines Agency will review any new information which may become available every year and this SmPC will be updated as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There were no apparent pharmacokinetic gender differences in patients with alpha-mannosidosis disease. <u>Absorption</u></p><p>Lamzede is administered through intravenous infusion. At steady-state after weekly infusion administration of 1 mg/kg of velmanase alfa, the mean maximum plasma concentration was about</p><p>8 &micro;g/mL and was reached at 1.8 hours after the start of administration corresponding to the mean infusion duration time.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>As expected for a protein of this size, the steady-state volume of distribution was low (0.27 L/kg), indicating distribution confined to plasma. The clearance of velmanase alfa from plasma (mean</p><p>6.7 mL/h/kg) is consistent with a rapid cellular uptake of velmanase alfa via mannose receptors.</p><p><u>Biotransformation</u></p><p>The metabolic pathway of velmanase alfa is predicted to be similar to other natural occurring proteins that degrade into small peptides and finally into amino acids.</p><p><u>Elimination</u></p><p>After the end of the infusion, velmanase alfa plasma concentrations fell in a biphasic fashion with a mean terminal elimination half-life of about 30 hours.</p><p><u>Linearity/(Non)linearity</u></p><p>Velmanase alfa exhibited a linear (i.e. first-order) pharmacokinetic profile, and C<sub>max</sub> and AUC increased proportionally to the dose with doses ranging from 0.8 to 3.2 mg/kg (corresponding to 25 and</p><p>100 units/kg).</p><p><u>Special populations</u></p><p>Velmanase alfa is a protein and is predicted to be metabolically degraded into amino acids. Proteins larger than 50,000 Da, such as velmanase alfa, are not eliminated renally. Consequently hepatic and renal impairment are not expected to affect the pharmacokinetic of velmanase alfa. As no patients older than</p><p>41 years have been identified across Europe, no relevant use in elderly patients is expected.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, juvenile toxicity and toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium phosphate dihydrate</p><p>Sodium dihydrogen phosphate dihydrate Mannitol</p><p>Glycine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

Reconstituted solution for infusion

Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C.
From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2&deg;C - 8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 mL vial (Type I glass) with a bromobutyl rubber stopper, an aluminium seal and a polypropylene flip off cap.</p><p>Each vial contains 10 mg of velmanase alfa.</p><p>Pack sizes of 1, 5 or 10 vials per carton. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lamzede requires reconstitution and is intended for intravenous infusion only. Each vial is for single use only.</p><p>&nbsp;</p><p><u>Instructions for reconstitution and administration</u></p><p>&nbsp;</p><p>Lamzede should be reconstituted and administrated by a healthcare professional.</p><p>Aseptic technique is to be used during preparation. Filter needles must not be used during preparation.</p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The number of vials to be used should be calculated based on the individual patient&rsquo;s weight. The recommended dose of 1 mg/kg is determined using the following calculation:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient&rsquo;s weight (kg) &times; dose (mg/kg) = Patient dose (in mg)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient dose (in mg) divided by 10 mg/vial (content of one vial) = number of vials to reconstitute. If the number of calculated vials includes a fraction, it should be rounded up to the next whole number.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Approximately 30 minutes prior to reconstitution, the required number of vials should be removed from the refrigerator. The vials should reach ambient temperature (between 15&deg;C and 25&deg;C) prior to reconstitution.</p><p>Each vial is reconstituted by slowly injecting 5 mL of water for injections to the inside of the wall of each vial. Each mL of reconstituted solution contains 2 mg of velmanase alfa. Only the volume corresponding to the recommended dose should be administered.</p><p>Example:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient&rsquo;s weight (44 kg) &times; dose (1 mg/kg) = Patient dose (44 mg)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44 mg divided by 10 mg/vial = 4.4 vials, therefore, 5 vials should be reconstituted.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From the total reconstituted volume, only 22 mL (corresponding to 44 mg) should be administered.</p><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The powder should be reconstituted in the vial by a slow drop-wise addition of the water for injections down the inside of the vial and not directly onto the lyophilised powder. Forcefully ejecting the water for injections from the syringe onto the powder should be avoided to minimise foaming. The reconstituted vials should stand on the table for about 5-10 minutes. Thereafter each vial should be tilted and rolled gently for 15-20 seconds to enhance the dissolution process. The vial should not be inverted, swirled, or shaken.</p><p>&nbsp;</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An immediate visual inspection of the solution for particulate matter and discoloration should be performed after reconstitution. The solution should be clear and <strong>not used if opaque particles are observed or if the solution is discoloured. </strong>Due to the nature of the medicinal product, the reconstituted solution may occasionally contain some proteinaceous particles in form of thin white strands or translucent fibers which will be removed by the in-line filter during infusion (see point e).</p><p>&nbsp;</p><p>d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The reconstituted solution is to be slowly withdrawn from each vial with caution to avoid foaming in the syringe. If the volume of the solution exceeds one syringe capacity, the required number of syringes should be prepared in order to replace the syringe quickly during the infusion.</p><p>&nbsp;</p><p>e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The reconstituted solution should be administered using an infusion set equipped with a pump and an in-line low protein-binding 0.22 &mu;m filter.</p><p>The total volume of infusion is determined by the patient&rsquo;s weight and should be administrated over a minimum of 50 minutes. For patients weighing less than 18 kg, and receiving less than 9 mL reconstituted solution, the infusion rate should be calculated so that the infusion time is</p><p>&ge;50 minutes. The maximum infusion rate is 25 mL/hour (see section 4.2). The infusion time can be calculated from the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Maximum infusion rate</strong></p><p><strong>(mL/h)</strong></p></td><td style="vertical-align:top"><p><strong>Minimum infusion time (min)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>6</strong></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>7</strong></p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>8</strong></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>9</strong></p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>10</strong></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>11</strong></p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>12</strong></p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>13</strong></p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>14</strong></p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>15</strong></p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>16</strong></p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>9.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>17</strong></p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>10.2</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>18</strong></p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>19</strong></p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top"><p>11.4</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>20</strong></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>21</strong></p></td><td style="vertical-align:top"><p>10.5</p></td><td style="vertical-align:top"><p>12.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>22</strong></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>13.2</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>23</strong></p></td><td style="vertical-align:top"><p>11.5</p></td><td style="vertical-align:top"><p>13.8</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>24</strong></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>14.4</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>26</strong></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>15.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>27</strong></p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>16.2</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>28</strong></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>16.8</p></td><td style="vertical-align:top"><p>50</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Maximum infusion rate</strong></p><p><strong>(mL/h)</strong></p></td><td style="vertical-align:top"><p><strong>Minimum infusion time (min)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>29</strong></p></td><td style="vertical-align:top"><p>14.5</p></td><td style="vertical-align:top"><p>17.4</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>31</strong></p></td><td style="vertical-align:top"><p>15.5</p></td><td style="vertical-align:top"><p>18.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>32</strong></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>19.2</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>33</strong></p></td><td style="vertical-align:top"><p>16.5</p></td><td style="vertical-align:top"><p>19.8</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>34</strong></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>20.4</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>35</strong></p></td><td style="vertical-align:top"><p>17.5</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>36</strong></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>21.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>37</strong></p></td><td style="vertical-align:top"><p>18.5</p></td><td style="vertical-align:top"><p>22.2</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>38</strong></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>22.8</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>39</strong></p></td><td style="vertical-align:top"><p>19.5</p></td><td style="vertical-align:top"><p>23.4</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>41</strong></p></td><td style="vertical-align:top"><p>20.5</p></td><td style="vertical-align:top"><p>24.6</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>42</strong></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p><strong>43</strong></p></td><td style="vertical-align:top"><p>21.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>52</p></td></tr><tr><td style="vertical-align:top"><p><strong>44</strong></p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>53</p></td></tr><tr><td style="vertical-align:top"><p><strong>45</strong></p></td><td style="vertical-align:top"><p>22.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>54</p></td></tr><tr><td style="vertical-align:top"><p><strong>46</strong></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>55</p></td></tr><tr><td style="vertical-align:top"><p><strong>47</strong></p></td><td style="vertical-align:top"><p>23.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>56</p></td></tr><tr><td style="vertical-align:top"><p><strong>48</strong></p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>58</p></td></tr><tr><td style="vertical-align:top"><p><strong>49</strong></p></td><td style="vertical-align:top"><p>24.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>59</p></td></tr><tr><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p><strong>51</strong></p></td><td style="vertical-align:top"><p>25.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>61</p></td></tr><tr><td style="vertical-align:top"><p><strong>52</strong></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>62</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Maximum infusion rate</strong></p><p><strong>(mL/h)</strong></p></td><td style="vertical-align:top"><p><strong>Minimum infusion time (min)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>53</strong></p></td><td style="vertical-align:top"><p>26.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>64</p></td></tr><tr><td style="vertical-align:top"><p><strong>54</strong></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>65</p></td></tr><tr><td style="vertical-align:top"><p><strong>55</strong></p></td><td style="vertical-align:top"><p>27.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>67</p></td></tr><tr><td style="vertical-align:top"><p><strong>56</strong></p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>67</p></td></tr><tr><td style="vertical-align:top"><p><strong>57</strong></p></td><td style="vertical-align:top"><p>28.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>68</p></td></tr><tr><td style="vertical-align:top"><p><strong>58</strong></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>70</p></td></tr><tr><td style="vertical-align:top"><p><strong>59</strong></p></td><td style="vertical-align:top"><p>29.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>71</p></td></tr><tr><td style="vertical-align:top"><p><strong>60</strong></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>72</p></td></tr><tr><td style="vertical-align:top"><p><strong>61</strong></p></td><td style="vertical-align:top"><p>30.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>73</p></td></tr><tr><td style="vertical-align:top"><p><strong>62</strong></p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>74</p></td></tr><tr><td style="vertical-align:top"><p><strong>63</strong></p></td><td style="vertical-align:top"><p>31.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>76</p></td></tr><tr><td style="vertical-align:top"><p><strong>64</strong></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>77</p></td></tr><tr><td style="vertical-align:top"><p><strong>65</strong></p></td><td style="vertical-align:top"><p>32.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>78</p></td></tr><tr><td style="vertical-align:top"><p><strong>66</strong></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>79</p></td></tr><tr><td style="vertical-align:top"><p><strong>67</strong></p></td><td style="vertical-align:top"><p>33.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>80</p></td></tr><tr><td style="vertical-align:top"><p><strong>68</strong></p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>82</p></td></tr><tr><td style="vertical-align:top"><p><strong>69</strong></p></td><td style="vertical-align:top"><p>34.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>83</p></td></tr><tr><td style="vertical-align:top"><p><strong>70</strong></p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>84</p></td></tr><tr><td style="vertical-align:top"><p><strong>71</strong></p></td><td style="vertical-align:top"><p>35.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>85</p></td></tr><tr><td style="vertical-align:top"><p><strong>72</strong></p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>86</p></td></tr><tr><td style="vertical-align:top"><p><strong>73</strong></p></td><td style="vertical-align:top"><p>36.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>88</p></td></tr><tr><td style="vertical-align:top"><p><strong>74</strong></p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>89</p></td></tr><tr><td style="vertical-align:top"><p><strong>75</strong></p></td><td style="vertical-align:top"><p>37.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p><strong>76</strong></p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>91</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Maximum infusion rate</strong></p><p><strong>(mL/h)</strong></p></td><td style="vertical-align:top"><p><strong>Minimum infusion time (min)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>77</strong></p></td><td style="vertical-align:top"><p>38.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>92</p></td></tr><tr><td style="vertical-align:top"><p><strong>78</strong></p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>94</p></td></tr><tr><td style="vertical-align:top"><p><strong>79</strong></p></td><td style="vertical-align:top"><p>39.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>95</p></td></tr><tr><td style="vertical-align:top"><p><strong>80</strong></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>96</p></td></tr><tr><td style="vertical-align:top"><p><strong>81</strong></p></td><td style="vertical-align:top"><p>40.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>97</p></td></tr><tr><td style="vertical-align:top"><p><strong>82</strong></p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>98</p></td></tr><tr><td style="vertical-align:top"><p><strong>83</strong></p></td><td style="vertical-align:top"><p>41.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p><strong>84</strong></p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>101</p></td></tr><tr><td style="vertical-align:top"><p><strong>85</strong></p></td><td style="vertical-align:top"><p>42.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>102</p></td></tr><tr><td style="vertical-align:top"><p><strong>86</strong></p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>103</p></td></tr><tr><td style="vertical-align:top"><p><strong>87</strong></p></td><td style="vertical-align:top"><p>43.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>104</p></td></tr><tr><td style="vertical-align:top"><p><strong>88</strong></p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>106</p></td></tr><tr><td style="vertical-align:top"><p><strong>89</strong></p></td><td style="vertical-align:top"><p>44.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>107</p></td></tr><tr><td style="vertical-align:top"><p><strong>90</strong></p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>108</p></td></tr><tr><td style="vertical-align:top"><p><strong>91</strong></p></td><td style="vertical-align:top"><p>45.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>109</p></td></tr><tr><td style="vertical-align:top"><p><strong>92</strong></p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>110</p></td></tr><tr><td style="vertical-align:top"><p><strong>93</strong></p></td><td style="vertical-align:top"><p>46.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>112</p></td></tr><tr><td style="vertical-align:top"><p><strong>94</strong></p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>113</p></td></tr><tr><td style="vertical-align:top"><p><strong>95</strong></p></td><td style="vertical-align:top"><p>47.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>114</p></td></tr><tr><td style="vertical-align:top"><p><strong>96</strong></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>115</p></td></tr><tr><td style="vertical-align:top"><p><strong>97</strong></p></td><td style="vertical-align:top"><p>48.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>116</p></td></tr><tr><td style="vertical-align:top"><p><strong>98</strong></p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>118</p></td></tr><tr><td style="vertical-align:top"><p><strong>99</strong></p></td><td style="vertical-align:top"><p>49.5</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>119</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When the last syringe is empty, the dosage syringe is replaced with a 20 mL syringe filled with sodium chloride 9 mg/mL (0.9%) solution for injection. A volume of 10 mL sodium chloride solution should be administered through the infusion system to infuse the remaining fraction of Lamzede in the line to the patient.</p><p>&nbsp;</p><p><u>Disposal</u></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chiesi Farmaceutici S.p.A. Via Palermo 26/A
43122 Parma Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>